COMMUNIQUÉS West-GlobeNewswire

Hop Valley Brewing Co. Makes Its Downtown Eugene Comeback with New Pub at 5th Street Public Market
14/09/2026
Hop Valley opens its new pub Sept. 17, giving Ducks fans a new place to rally, celebrate, and raise a pint on game day EUGENE, Ore., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Hop Valley Brewing Co , a trailblazer in the craft [...]
Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
14/09/2026
U.S. FDA (Office of Orphan Products Development) grants Orphan Drug Designation for Sovateltide, a potential first-in-class therapy that could transform the treatment of Neonatal Hypoxic-Ischemic Encephalopathy Five [...]
Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development
14/09/2026
Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entity HIGHLIGHTS Texas-based company [...]
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
14/09/2026
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell [...]
Soleo Health Expands Atlanta Footprint With Infusion Centers In Woodstock and Fayetteville, Georgia
14/09/2026
FRISCO, Texas, WOODSTOCK, Ga., and FAYETTEVILLE, Ga., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Soleo Health, an innovative leader and national, independent provider of complex specialty pharmacy and infusion services , [...]
GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
14/09/2026
Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the “dark genome” of all people. K Env is found in the [...]
Slate Medicines Appoints Kenneth Koblan, PhD, as Chief Scientific Officer
14/09/2026
RALEIGH, N.C., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Slate Medicines Inc. (“Slate”), a clinical-stage biotechnology company committed to advancing innovative new therapies that may broaden the treatment paradigm and [...]
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
14/09/2026
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 [...]
Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
14/09/2026
- Pasithea has been selected to present cutaneous neurofibromas (CN) clinical data in an oral presentation - Pasithea has been selected to present plexiform neurofibromas (PN) clinical data in a poster presentation - [...]
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
14/09/2026
Company to host a virtual event today at 8:00 a.m. ET CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential [...]
As New York Fashion Week Kicks Off, Kraig Labs Advances Spider Silk for Fashion's Next Generation of Designers
14/09/2026
Fashion industry shift puts new focus on bio-based and innovative textiles as Kraig Labs scales recombinant spider silk for potential luxury and performance applications ANN ARBOR, Mich., Sept. 14, 2026 (GLOBE NEWSWIRE [...]
NANOBIOTIX annonce les résultats complets de la phase 1 pour JNJ-1900 (NBTXR3) dans le cancer du poumon non à petites cellules inopérable et récurrent
14/09/2026
L’ensemble des 24 patients a été traité sans toxicité limitant la dose, sans événement indésirable de grade 3 ou supérieur liés à JNJ-1900 (NBTXR3) ou à la procédure d’injection, et l’injection intratumorale a été jugée [...]
NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer
14/09/2026
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasible One- [...]
Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee
14/09/2026
LONDON and PHILADELPHIA, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, today [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
14/09/2026
COPENHAGEN, Denmark, September 14, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Cellectis annonce sa transformation stratégique en société d'édition du génome in vivo
14/09/2026
Cellectis fait progresser ses deux programmes in vivo phares, .HEAL-101 et .HEAL-201 dans les dyslipidémies sévères, avec des données préliminaires de phase 1 attendues respectivement au second semestre 2027 et au [...]
Cellectis Announces Strategic Transformation To In Vivo Gene Editing Company
14/09/2026
Cellectis to advance two lead in vivo programs .HEAL-101 and .HEAL-201 in severe dyslipidemias with preliminary Phase 1 data planned in H2 2027 and H1 2028, respectively Transformation supported by continuing existing [...]
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
14/09/2026
Bagsværd, Denmark, 14 September 2026 – Novo Nordisk marked the beginning of its next chapter today by unveiling a rebrand centred on ‘Lasting Health Starts Now’, and the single ‘Novo’ name, and by updating its culture [...]
Initiation of Novonesis’ share buyback program
14/09/2026
Today, Novonesis will initiate the first tranche (the “First Tranche”) of the EUR 1 billion multi-year share buyback program announced in Company Announcement No. 14, on August 19, 2026. Under the First Tranche, [...]

Pages